Orphenadrine
Active ingredient
- Drug class
- -
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 2
Overview
Plain-language summary, compiled from the cited regulatory records
Orphenadrine citrate extended-release tablets are indicated for the relief of discomfort associated with acute painful musculoskeletal conditions [1]. It is used as an adjunct to rest, physical therapy, and other measures to manage these conditions [1].
Orphenadrine citrate belongs to a class of drugs that are used to treat muscle spasms and pain [1]. This medication works by blocking nerve impulses that are sent to the brain, which can help to reduce pain and relax muscles [1]. It is important to note that orphenadrine citrate is not a substitute for rest, physical therapy, or other recommended treatments for musculoskeletal issues [1].
Orphenadrine citrate is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | January 1, 2026 |
| GB United Kingdom | MHRA | 1 | March 6, 2026 |
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.
How to take
GBUnited Kingdom· MHRA
1 product
Uses
Anticholinergic, for the treatment of all forms of Parkinsonism, including drug induced (neuroleptic syndrome).
How to take
Drug interactions
Known interactions involving Orphenadrine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 399. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 106be130-b4f8-5c… · revised January 1, 2026 [PDF]
- [2]MHRA (UK) · PL004270076 · revised March 6, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.